Larimar Therapeutics Inc.

LRMR | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.83

+$0.04 (+1.06%)

At close: Sep 21, 2026, 4:00 PM ET

$3.83

$0 (0.00%)

Pre-market: Sep 22, 2026, 7:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.06%

(1D)

Rating

Updated: Sep 12, 2026

21.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $397.87M

1D Range

3.81 3.89

52W Range

2.72 6.42

Valuation (TTM)

PE -1.92

PB 3.12

EV/EBITDA -1.43

Valuation (NTM)

Forward PE N/A

Forward PEG 0.13

Price Target $8

Cash Flow

FCF Yield -39.2%

SBC Adj. FCF Yield -41.1%

SBC Impact -4.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -27.9% | 1.6%

FCF 3Y | 5Y -57.9% | -43.1%

Returns

ROA -104.4%

ROE -137.4%

ROIC -135.3%

Financial Health

Net Cash

$156.27M

Current Ratio 4.70

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a dis...

Sector Healthcare

Industry Biotechnology

Employees 71

IPO Date Jun 18, 2014

Website www.larimartx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+108.88%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞